GlassScriptPhysician profile
Jillian L Oakleaf
NPI 1477904050
$15,422.99
in general payments reported to CMS, 2019-2025
38 companies · $4,214 in 2025
The $4,214 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,950 · 2022: $468 · 2023: $3,067 · 2024: $3,724 · 2025: $4,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,751 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Education: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,751.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Education | $753.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,495.89 | 2021-2025 | Calquence, Lynparza, Tagrisso |
| Karyopharm Therapeutics INC. | $3,655.62 | 2021 | |
| Janssen Biotech, INC. | $1,342.79 | 2021-2025 | Erleada, Talvey, Tecvayli |
| Dendreon Pharmaceuticals LLC | $692.28 | 2024-2025 | Provenge |
| Astellas Pharma US INC | $579.91 | 2022-2025 | Xospata, Xtandi |
| Pfizer INC. | $480.24 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $442.03 | 2024-2025 | Gemtesa, Orgovyx |
| Novartis Pharmaceuticals Corporation | $278.97 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $277.99 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Kite Pharma, INC. | $271.19 | 2022-2023 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $231.24 | 2025 | |
| Urogen Pharma, INC. | $147.48 | 2024-2025 | |
| Accord Healthcare, INC. | $117.96 | 2024-2025 | |
| Daiichi Sankyo INC. | $111.65 | 2022-2024 | Enhertu, Injectafer |
| Vertex Pharmaceuticals Incorporated | $109.19 | 2024-2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epizyme, INC. | $103.43 | 2021 | |
| Olympus America INC. | $94.79 | 2025 | Itind System |
| Tolmar, INC. | $92.25 | 2024-2025 | Eligard, Jatenzo |
| Telix Pharmaceuticals | $89.06 | 2025 | Illuccix |
| Takeda Pharmaceuticals U.S.A., INC. | $89.00 | 2023 | |
| Genzyme Corporation | $79.05 | 2021-2024 | |
| Immunitybio, INC. | $76.21 | 2025 | |
| Abbvie INC. | $55.00 | 2021-2025 | |
| Endo USA, INC. | $54.61 | 2024-2025 | Xiaflex |
| Myriad Genetic Laboratories, INC. | $53.26 | 2024-2025 | Prolaris |
| Amgen INC. | $49.13 | 2021-2022 | |
| Antares Pharma, INC. | $47.29 | 2025 | Xyosted |
| Sun Pharmaceutical Industries INC. | $43.06 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $41.83 | 2021-2022 | |
| Seagen INC. | $41.30 | 2021-2023 | Adcetris |
| Coloplast Corp | $33.39 | 2025 | |
| Verity Pharmaceuticals INC. | $31.36 | 2025 | Trelstar |
| Pharmaessentia USA Corporation | $22.86 | 2023 | Besremi |
| Alexion Pharmaceuticals, INC. | $21.23 | 2024 | Ultomiris |
| Genentech USA, INC. | $20.62 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.88 | 2021 | |
| Celgene Corporation | $16.62 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.33 | 2025 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Oakleaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.